目录产品 » ALK-7/Activin RIC, His, Human
Manual
Manual
COAs

ALK-7/Activin RIC, His, Human

该产品已下架。
Arterial stiffness is an important feature of diabetic macrovascular complications. Activin receptor-like kinase 7 (ALK7), a member of type I transforming growth factor-β (TGF-β) receptors, is correlated with pathogenic risks of type 2 diabetes mellitus and cardiovascular diseases and may be involved in cardiovascular remodeling.
Z05006
产品简介
Species Human
Protein Construction
ALK-7/Activin RIC (Glu21-Glu113)_x000D_
Accession # Q8NER5-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 11.11 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 20-40 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in 20mM Tris, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background Arterial stiffness is an important feature of diabetic macrovascular complications. Activin receptor-like kinase 7 (ALK7), a member of type I transforming growth factor-β (TGF-β) receptors, is correlated with pathogenic risks of type 2 diabetes mellitus and cardiovascular diseases and may be involved in cardiovascular remodeling.
Synonyms ACTR-IC; ACVR1C; ALK7; Activin R1C;
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.